For instance, studies have shown that blocking IL-1β in K-ras mutant lung adenocarcinoma (KM-LUAD) mice, which express high levels of IL-1β in the lungs, significantly reduces tumor load when IL-1β monoclonal antibodies are administered at 6 and 14 weeks of age (47). This evidence concerns the gene KRAS and neoplasm.